Analytical Data
-
Gene name
CD160
-
简介
CD160 Protein, Rhesus macaque (HEK293, Fc) is a recombinant rhesus macaque CD160 expressed in HEK 293 cells with a C-Fc tag at the C-terminus. CD160 Protein binds weakly to MHC I and stimulates NK and CD8+ T‐cell activation[1][2].
- Application
-
Alternative Names
rRhCD160, C-Fc; CD160 antigen; CD160
-
Species
Rhesus Macaque
-
Source
HEK293
-
Tag
C-Fc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
G7MG20
-
Expression Region
G25-L158
-
Protein Length
Partial
-
Molecular Weight
55-65 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD160, also known as BY55, is an immune checkpoint receptor primarily expressed on the surface of certain immune cells such as natural killer (NK) cells and activated T cells. Its role in immunoregulation has garnered significant interest, particularly in the context of cancer immunotherapy. CD160 interacts with its ligands, which can inhibit immune responses, thus playing a critical role in maintaining immune homeostasis and potentially contributing to tumor immune evasion. Research has shown that CD160 can modulate the activation and cytotoxicity of NK cells, influencing tumor surveillance and the effectiveness of anti-tumor immunity. As a result, the development of CD160 recombinant proteins has emerged as a promising avenue for therapeutic interventions. Researchers are investigating how these proteins can be utilized to enhance immune responses against tumors, block inhibitory signals, and improve the efficacy of existing immunotherapies. The understanding of CD160's structure-function relationship, its signaling pathways, and ligand interactions is crucial for the design of novel targeted therapies. Additionally, CD160's potential as a biomarker for predicting clinical outcomes in cancer patients further emphasizes its importance in the field of immunology and oncology. Overall, the study of CD160 and its recombinant proteins holds significant promise for advancing cancer treatment strategies, potentially leading to more effective therapies that harness the body’s immune system to combat malignancies.
